Abstract
Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Biologic Agents for Treatment of Rheumatoid Arthritis
Volume: 9 Issue: 1
Author(s): Bulent Butun
Affiliation:
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Abstract: Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Export Options
About this article
Cite this article as:
Butun Bulent, Biologic Agents for Treatment of Rheumatoid Arthritis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711692
DOI https://dx.doi.org/10.2174/187152310790711692 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Editorial: Nailfold Capillaroscopy in Rheumatology
Current Rheumatology Reviews Post-Panning Computer-Aided Analysis of Phagotope Collections Selected with Neurocysticercosis Patient Polyclonal Antibodies Separation of Disease-Relevant and Irrelevant Peptide Sequences
Combinatorial Chemistry & High Throughput Screening Update on Targets of Biologic Therapies for Rheumatoid Arthritis
Current Rheumatology Reviews Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Current Drug Targets - Inflammation & Allergy The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design Physicochemical and Biological Aspects of Curcumin: A Review
The Natural Products Journal Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Somatostatin Involvement in Rheumatoid Arthritis
Current Rheumatology Reviews 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) OA-4 Inhibits Osteoclast Formation and Bone Resorption via Suppressing RANKL Induced P38 Signaling Pathway
Current Medicinal Chemistry Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Pharmaceutical Green Chemistry Applied to the Chemical Synthesis of Steroid Compounds
Current Green Chemistry Patents in Targets and Drugs for Unbalanced Cytokine and Chemokine Network Mediated Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of COVID-19
Drug Delivery Letters Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design